Results 261 to 270 of about 11,581,273 (293)
Some of the next articles are maybe not open access.
Fibroblast Growth Factor 23 and Klotho Are Present in the Growth Plate
Connective Tissue Research, 2013Regulation of phosphate homeostasis is essential for mineralization and enchondral ossification. Fibroblast growth factor 23 (FGF23) and its obligatory co-receptor Klotho (KL) play a key role in this process by influencing both renal phosphate reabsorption and vitamin D metabolism. In disease, excessive action of FGF23 leads to hypophosphatemic rickets,
Adalbert, Raimann +5 more
openaire +2 more sources
Inherited fibroblast growth factor 23 excess
Best Practice & Research Clinical Endocrinology & MetabolismSyndromes of inherited fibroblast growth factor 23 (FGF-23) excess encompass a wide spectrum that includes X-linked hypophosphataemia (XLH), autosomal dominant and recessive forms of rickets as well as various syndromic conditions namely fibrous dysplasia/McCune Albright syndrome, osteoglophonic dysplasia, Jansen's chondrodysplasia and cutaneous ...
Kripa Elizabeth, Cherian +1 more
openaire +2 more sources
Fibroblast growth factor 23 as a phosphotropic hormone and beyond
Journal of Bone and Mineral Metabolism, 2011Fibroblast growth factor 23 (FGF23) is produced by bone and reduces serum phosphate by inhibiting proximal tubular phosphate reabsorption and intestinal phosphate absorption. Excess actions of FGF23 cause several kinds of hypophosphatemic rickets/osteomalacia while deficient actions of FGF23 result in hyperphosphatemic tumoral calcinosis.
Seiji, Fukumoto, Yuichiro, Shimizu
openaire +2 more sources
Fibroblast growth factor 23 in untreated nephrotic syndrome
Nephrology, 2018AbstractAimDespite its importance in bone and cardiovascular disease in subjects with kidney disease, there are no data on fibroblast growth factor 23 (FGF23) perturbations in nephrotic syndrome. We evaluated FGF23 and markers of mineral bone metabolism in subjects with untreated NS.MethodsIn this cross‐sectional study, we measured circulating levels ...
Ashok Kumar, Yadav +5 more
openaire +2 more sources
Fibroblast Growth Factor-23 and Phosphorus Metabolism
2011The understanding of phosphorus metabolism has expanded considerably over the last decade. Recent studies have identified a novel bone-kidney endocrine axis that maintains phosphate homeostasis. When phosphate is in excess, FGF-23 is secreted from bone and acts on the kidney to promote phosphate excretion into urine and to suppress vitamin D synthesis,
openaire +2 more sources
The phosphate regulating hormone fibroblast growth factor‐23
Acta Physiologica, 2010AbstractOver the last decade, the regulation of phosphate (Pi) homeostasis has been under intense investigation. By utilizing modern biochemical and genetic tools, the pathophysiological mechanisms behind several known hereditary and acquired hypo‐ and hyperphosphatemic diseases have been clarified. The results of these efforts have opened new insights
R, Marsell, K B, Jonsson
openaire +2 more sources
The couple fibroblast growth factor 23 (FGF23)/Klotho
Annales de biologie clinique, 2015The fibrobalst growth factor 23 (FGF23) is a protein secreted in the plasma by bone cells. FGF23 controls phosphate and calcitriol plasma concentration. Its main physiological targets are the kidney and the parathyroid gland. Its production is stimulated by phosphate intake and plasma calcitriol levels.
openaire +2 more sources
Anti-fibroblast growth factor 23 antibody therapy
Current Opinion in Nephrology and Hypertension, 2014The review is intended to provide an update on the expanding knowledge regarding diseases caused by the excess actions of fibroblast growth factor 23 (FGF23) and also on the new therapeutic measures for these diseases, with an emphasis on the anti-FGF23 antibody.FGF23 decreases serum phosphate and 1,25-dihydroxyvitamin D levels.
openaire +2 more sources